![Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG | Leukemia Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2013.297/MediaObjects/41375_2014_Article_BFleu2013297_Fig1_HTML.jpg)
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG | Leukemia
![Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers](https://www.mdpi.com/cancers/cancers-13-00966/article_deploy/html/images/cancers-13-00966-g001.png)
Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
![Mitigating acute chemotherapy-associated adverse events in patients with cancer | Nature Reviews Clinical Oncology Mitigating acute chemotherapy-associated adverse events in patients with cancer | Nature Reviews Clinical Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41571-022-00685-3/MediaObjects/41571_2022_685_Fig1_HTML.png)
Mitigating acute chemotherapy-associated adverse events in patients with cancer | Nature Reviews Clinical Oncology
![Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial - Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial -](https://www.thelancet.com/cms/attachment/e536a65e-d14b-44c1-b513-70fa78cde00f/gr1.gif)
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial -
![Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-018-0268-9/MediaObjects/41375_2018_268_Fig1_HTML.png)
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia
![Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/3865e364-f642-4c4c-b7f0-832d633f64f5/joim13553-gra-0001-m.jpg)
Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library
![Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12951-023-01881-8/MediaObjects/12951_2023_1881_Sch1_HTML.png)
Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text
![Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function - ScienceDirect Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0891584918307457-fx1.jpg)
Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function - ScienceDirect
![Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12951-023-01881-8/MediaObjects/12951_2023_1881_Fig3_HTML.png)